These differences were probably related to the severity of the disease, which was also indirectly confirmed by us in previous studies demonstrating the highest values of the activity of MBP-hydrolyzing antibodies with negative symptoms [30], during exacerbation of the disease, and in patients with continuous schizophrenia [20]. This evidence concerns the gene MBP and schizophrenia.